MedTrace Logo

Curcumin for Type 2 Diabetic Patients

NCT01052597 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2010-01-20

No results posted yet for this study

Summary

There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.

Conditions

Interventions

DRUG

curcumin

Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

Sponsors & Collaborators

  • Ministry of Health, Thailand

    collaborator OTHER_GOV

  • Srinakharinwirot University

    lead OTHER

Principal Investigators

  • Somlak Chuengsamarn, Medical Doctor · Srinakarinwirot University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-02-28
Completion
2010-03-31

Countries

  • Thailand

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052597 on ClinicalTrials.gov